Please login to the form below
COVID-19 vaccine
This page shows the latest COVID-19 vaccine news and features for those working in and with pharma, biotech and healthcare.
BioNTech reveals plans to spend about €1bn more on research and development this year
The plans come after BioNTech ended 2022 with a cash balance of 13.9bn plus receivables, largely attributed to its COVID-19 vaccine market lead with partner Pfizer. ... BA.5 adapted bivalent COVID-19 vaccine.
Latest news
-
Pfizer/BioNTech’s Omicron-adapted booster approved by FDA for young children
Pfizer and BioNTech’s Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine has been authorised by the US Food and Drug Administration (FDA) for emergency use as a single ... Recent real-world evidence has also shown the bivalent vaccine to be protective
-
Pfizer/BioNTech submit FDA application for Omicron-adapted booster for young children
Pfizer and BioNTech have submitted an application to the US Food and Drug Administration (FDA) for the emergency use of their Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine ... Vaccine manufacturers have been focused on the development of variant
-
GSK and Vir Biotech amend COVID-19 research partnership
Vir will now advance new antibodies and vaccines for COVID-19 alone or with other partners. ... Under the terms of the amended agreement, Vir retains the sole rights to continue advancing solutions arising from the collaborative COVID-19 vaccine and
-
JCVI recommends autumn COVID-19 vaccine booster for those at highest risk
The Joint Committee on Vaccination and Immunisation (JCVI) has advised the UK government that those at a higher risk of severe COVID-19 should be offered a booster vaccination this autumn. ... He also added that the committee will be providing final
-
Moderna reports positive phase 3 data for its RSV vaccine for older adults
infectious disease vaccine platform after Spikevax, our COVID-19 vaccine. ... disease, including COVID-19, influenza and human metapneumovirus.”.
More from news
Approximately 17 fully matching, plus 483 partially matching documents found.
Latest Intelligence
-
Unlocking the potential of data sharing
market. How Brexit has affected data sharing in clinical trials. During COVID-19, we saw how important it was for countries to share information quickly, which was bourne out by the ... approval, in record time, of the first COVID-19 vaccine.
-
Creating the urgency and drive needed to tackle antimicrobial resistance
However, it is not that HCPs are just talking about AMR in the context of COVID-19. ... It has highlighted some opportunities such as the speed of the COVID-19 vaccine development being translated into the search for vaccines to address AMR, as
-
Customers, content and change
with the express mission of introducing a COVID-19 vaccine to the UK. ... However, the huge success of its COVID-19 vaccine was not without its roll-out challenges.
-
Creating strong employee engagement and retaining talent in the new normal
While COVID-19 challenged all of us working in medcomms and our clients, it also created opportunities for fresh thinking. ... To provide clarity to HCPs treating MS patients about using the COVID-19 vaccine, we built a fully remote community of experts
-
AI: powering healthcare, empowering patients Physician perceptions of AI and the future of pharma
For example, it contributed significantly to the speed and success of the COVID-19 vaccine effort, particularly via the screening of molecules as potential drugs, both novel and repurposed. ... Like the COVID-19-induced paradigm shift in vaccine
More from intelligence
Approximately 0 fully matching, plus 20 partially matching documents found.
Latest from PMHub
-
There's power in collaboration
Just look at the success of the Covid-19 vaccine development… from the collaboration between AstraZeneca, Oxford University and it’s Vaccitech company to the partnership between BioNTech, Fosun Pharma and ... Pfizer, the fastest development of a
-
Bedrock’s Accelerated Virtual Consensus Programme for Merck wins at Communiqué Awards
COVID-19 vaccination’. ... The consensus programme outputs were designed to provide clarity to HCPs treating MS patients about using the COVID-19 vaccine.
-
Diversity in Clinical Trials: A more inclusive approach in patient recruitment
We have seen a growing focus on patient diversity in clinical trials in recent years, but the COVID-19 vaccine trials in particular have highlighted the importance of achieving diverse patient
-
Reflections on the MAPS EMEA 2022 Annual Meeting
BioNTech’s Project Lightspeed is a case study in this – setting the highest standard to accelerate the development and commercialization of a COVID-19 vaccine in record time.
-
What does the future hold for clinical trial recruitment?
This work is ongoing as the virus mutates; last month, it was announced that Pfizer and BioNTech had started clinical trials for a new Covid vaccine targeting the Omicron variant. ... While Covid-19 vaccine trials have garnered headlines these have
More from PMHub
Approximately 2 fully matching, plus 35 partially matching documents found.
Subscribe to our email news alerts
- Strategy Director - Healthcare Advertising
- Highly competitive salary
-
Omnichannel Account Director
- £55,000 - £65,000 yearly
-
Senior Medical Writer
- Highly competitive salary
- Associate Director - Global Healthcare Consulting
- Highly competitive salary
-
Pharmacovigilance Project Lead
- Highly competitive salary
-
Pharmacovigilance Manager
- Highly competitive salary
-
Technical Sales Representative
- Highly competitive salary
- Early Access Program - Regulatory Affairs (EAP-RA)
- Highly competitive salary
- MHRA to introduce new UK clinical trials framework
- AbbVie’s Parkinson’s disease therapy application rejected by FDA
- Roche and Eli Lilly to collaborate on Alzheimer’s disease blood test
- Takeda presents positive phase 2b results for TAK-279 in plaque psoriasis
- FDA proposes improvements for oncology clinical trials supporting accelerated approval
- Novo Nordisk and Dewpoint partner on insulin resistance drug candidates
- PMGroup announces launch of new recruitment platform PharmaRole
- Merck reports positive results for Keytruda plus chemotherapy in endometrial cancer
- BioNTech reveals plans to spend about €1bn more on research and development this year
- AstraZeneca’s mild combination asthma reliever approved in UK
- Virtual Patient Engagement Program: A Customer Story
- Putting Skin in the Game at AAD 2023
- Locus Biosciences announces first patient treated in urinary tract infection trial
- Team ITG appoints Gerhard Arnhofer as head of customer strategy for life sciences division
- Merck reports positive results for Keytruda plus chemotherapy in endometrial cancer
- Takeda presents positive phase 2b results for TAK-279 in plaque psoriasis
- Sanofi/Regeneron’s Dupixent approved by EC for atopic dermatitis in children
- Inizio appoints Stefanie Christmas as global head of DE&I
PMHub
Say Communications
We focus on what matters most…. Driven by insight, expertise and fresh thinking, our award-winning communications programmes are designed to...
Latest intelligence
- Virtual Patient Engagement Program: A Customer Story
- Our client wanted to better understand the needs, preferences, and treatment gaps among adult patients with a rare genetic disease......
- Humancomms for humancare?
- Paul Hutchings, founder of fox&cat, writes on the role of humour in healthcare comms: PharmaComms 2023...
- Rare diseases: not so rare after all
- The brave new world addressing rare diseases – a way ahead to better and more inclusive treatment...
